Neil Kumar sold $5.4M of BBIO
Chief Executive Officer at BridgeBio Pharma, Inc.. 80,000 shares at an average of $67.40, traded May 7, 2026, filed May 11, 2026.
Score components
- +25RoleCEO
- +25Trade size$5.4M at market
- +5Share of holdings soldSold 13% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +4.2%, 3m +30.9%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001470831-26-000423, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -11,217 | $67.50 | $757k | 584,469 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,333 | $68.38 | $570k | 576,136 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -450 | $69.09 | $31k | 575,686 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -11,217 | $67.49 | $757k | 4,387,230 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -8,334 | $68.38 | $570k | 4,378,896 | May 11, 2026 |
| May 7, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -449 | $69.09 | $31k | 4,378,447 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -13,973 | $66.65 | $931k | 561,713 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,077 | $67.35 | $342k | 556,636 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -950 | $68.35 | $65k | 555,686 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -13,974 | $66.65 | $931k | 4,364,473 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -5,076 | $67.35 | $342k | 4,359,397 | May 11, 2026 |
| May 8, 2026 | SOpen-market sale Common Stockindirect: By Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee.10b5-1 | -950 | $68.35 | $65k | 4,358,447 | May 11, 2026 |
Related signals
Other insiders at BridgeBio Pharma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $691k 10,000 shares | -2% | |
| 35Weak | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $3.7M 44,980 shares | -16% | |
| 6Weak | BridgeBio Pharma, Inc. | Maricel Apuli Chief Accounting Officer | $160k 2,000 shares | -2% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $13M 148,589 shares | -95% | |
| 23Weak | BridgeBio Pharma, Inc. | Andrea Ellis director | $1.4M 17,167 shares | -43% | |
| 13Weak | BridgeBio Pharma, Inc. | Hannah Valantine director | $342k 5,004 shares | -35% | |
| 33Weak | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $2.8M 39,363 shares | -372% | |
| 40Moderate | BridgeBio Pharma, Inc. | Jennifer E. Cook director | $6.0M 90,240 shares | -93% | |
| 43Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $5.4M 80,000 shares | -14% | |
| 45Moderate | BridgeBio Pharma, Inc. | Neil Kumar Chief Executive Officer | $1.8M 26,103 shares | -10% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.